Leucoencefalopatía Multifocal Progresiva causada por Virus JC
DOI:
https://doi.org/10.34119/bjhrv7n4-032Keywords:
Leucoencefalopatía Multifocal Progresiva, virus JC, VIH, síntomas neurológicosAbstract
La leucoencefalopatía multifocal progresiva (LMP) es una enfermedad poco común y catastrófica que afecta la mielina, la capa protectora de los nervios en el cerebro, causando daño en la sustancia blanca cerebral. Esta enfermedad es ocasionada por el virus JC, un tipo de poliomavirus humano que generalmente se contrae durante la infancia y solo conduce a esta afección. La LMP es más frecuente en personas con sistemas inmunológicos debilitados, especialmente aquellos que son portadores del virus de la inmunodeficiencia humana (VIH). Las lesiones desmielinizantes provocan una variedad de síntomas neurológicos que requieren un diagnóstico preciso y confiable para distinguirla de otras condiciones.
References
Morcillo Andrés, et al. Leucoencefalopatía multifocal progresiva. Acta Neurol Colomb. 2021; 37(1).
Caporro Julieta, et al. Espectro clínico de la leucoencefalopatía multifocal progresiva: diferencias y similitudes en pacientes con y sin virus de la inmunodeficiencia humana. Rev. neurol. (Ed. impr.). 2019; 69(4): p. 152-158.
Valverde G,SR&SC. Las Enfermedades Reumáticas como Factor de Riesgo en el Desarrollo de la Leucoencefalopatía Multifocal Progresiva. Revista Clínica de Medicina UCR-HSJD. 2020; 10(4).
I. Cortese DR&AN. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology. 2021; 17: p. 37–51.
MR H. Discovery of simisn virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand. 1998; 94: p. 183-190.
RJ F. Rearranged and chimaeric primate polyomavirus genomes. Dev Biol Stand. 1998; 94: p. 103-113.
Chatterjee M WT&FR. Identification of archetype and rearranged forms of BK virus in leukocytes from healthy individuals. J Med Virol 60. 2000; 60: p. 353-362.
Monaco M., et al. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J. Virol. 2001; 75: p. 87-95.
Moens U., et al. Serological cross-reactivity between human polyomaviruses. Rev. Med. Virol. 2013; 23: p. 250–264.
Moens U. Biology, evolution, and medical importance of polyomaviruses: an update. Infect. Genet. Evol. 2017;: p. 18–38.
T. Panchabhai et al. Progressive Multifocal Leukoencephalopathy in a LunTransplant Recipient: Isolation of John Cunningham (JC) Virus from Bronchoalveolar Lavage. J Glob Infect Dis. 2016; 8(1): p. 51-4.
V. Pietropaolo et al. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. New Microbiol. 2018; 41(3): p. 179-186.
A. Butic ea. Polyomavirus Wakes Up and Chooses Neurovirulence. Viruses. 2023; 15(10).
Cáceres J, et al. Leucoencefalopatía multifocal progresiva: enfermedad grave en el paciente inmunosuprimido. Reporte de caso. Acta Neurol Colomb. 2023; 38(4).
Yang J, et al. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 2022; 28(1): p. 7-15.
Kartau M, et al. The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study. Open Forum Infect Dis. 2019.
B ZS&B. Progressive multifocal leukoencephalopathy. Handb Clin Neurol. 2018; 152: p. 123-137.
Harypursat V,et al. C Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review. AIDS Res Ther. 2020; 17.
Medrano C, et al. Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. Emerg Infect Dis. 2019; 25(11): p. 2145–2147.
Morcillo A,et al. Leucoencefalopatía multifocal progresiva. Acta Neurol Colomb. 2021; 37(1).
O´ Hara B,et al. JC Virus infected choroid plexus epithelial cells produce extracellular vesicles that infect glial cells independently of the virus attachment receptor. Plos Pathogens. 2020; 16(3).
Saxena R, et al. Human neurotropic polyomavirus, JC virus, agnoprotein targets mitochondrion and modulates its functions. Virology. 2021; 553: p. 135-153.
Seung-yoon Lee ea. Progressive multifocal leukoencephalopathy diagnosed by brain biopsy, not by the DNA test for JC Virus. 2019; 14(1): p. 240-244.
Wijburg M, et al. Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 2018;(75): p. 827–833.
Mahler C, et al. Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm. 2020; 7(4).
Corey S, et al. Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV. Curr HIV/AIDS Rep. 2022; 19(6).
Muftuoglu M. ea. Adoptive transfer of JC virus-specific R lymphocytes or the treatment of progressive multifocal leukoencephalopathy. Engl J Med. 2018; 379(15): p. 1443–1451.
Berzero G. et al. Adoptive transfer of JC virus-specific R lymphocytes or the treatment of progressive multifocal leukoencephalopathy. Ann Neurol 2021. 2021; 89(4).
Fitzgerald S. Patients with PML might be helped by T-Cell Therapy, but more research Is needed. Neurology Today. 2021.
Cortese I, et al. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol. 2021; 20(8): p. 639-652.
Goldman A, et al. Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood. 2023; 9(141): p. 673-677.
Koralnik IJ. Up to Date. [Online].; 2023. Available from: https://medilib.ir/uptodate/show/1697.
Kartau M,ea. Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis. 2019; 2(9).
Bernard R,et al. Advances in Treatment of Progressive Multifocal Leukoencephalopathy. Ann Neurol. 2021; 90(6): p. 865-873.
